Xiaoling Ma | Medicine | Best Researcher Award

Posted on by sciencefather

Prof. Xiaoling Ma | Medicine | Best Researcher Award

Chief physician | The first hospital of Lanzhou university | China

Dr. Xiaoling Ma is a distinguished Chief Physician and Associate Professor, currently serving as the Director of the Reproductive Medicine Center at The First Hospital of Lanzhou University. With over two decades of experience in reproductive medicine, she has made significant contributions to the advancement of assisted reproductive technology (ART). Dr. Ma is a nationally recognized expert in ART management and holds key positions in several prestigious reproductive medicine organizations in China. Her expertise encompasses reproductive endocrinology, fertility preservation, and genetic screening technologies.

Profile👤

Scopus

Strengths for the Awards✨

✅ Extensive Research Contributions: Xiaoling Ma has published over 30 articles in SCI and core Chinese journals, indicating a strong research output. Recent publications in Biomedicine & Pharmacotherapy, Reproductive Sciences, and BMC Medical Genomics highlight her contributions to reproductive medicine.

✅ Leading Research and Innovation: She has led multiple national and provincial research projects, including studies on reproductive genetics, fertility preservation, and endometriosis mechanisms.

✅ Academic and Professional Influence: As a chief physician, associate professor, and director of the Reproductive Medicine Center, her influence extends to clinical practice, academic mentorship, and policy advisory roles.

✅ Editorial and Professional Leadership: Serving as the Chinese editor for Human Reproduction Update and holding key roles in reproductive medicine associations in China demonstrate her leadership in the field.

🎓 Education

Dr. Xiaoling Ma obtained her Master’s degree in Medicine from a renowned Chinese institution. She has pursued extensive postgraduate training and specialized programs in reproductive medicine, refining her knowledge in assisted reproductive technology, reproductive endocrinology, and genetic screening. Her continuous pursuit of academic excellence has positioned her as a leading educator and mentor in reproductive healthcare.

💼 Experience

With a distinguished career spanning over 20 years, Dr. Ma has been instrumental in pioneering and implementing ART techniques. She has successfully led numerous national and provincial medical projects in China, focusing on fertility evaluation, genetic screening, and reproductive health. In addition to her clinical practice, she plays a pivotal role in policy-making and regulatory aspects of reproductive medicine, ensuring the ethical implementation of ART procedures. As an educator, she has trained and mentored countless physicians, enhancing the field of reproductive medicine across China.

🔬 Research Interests On Medicine

Dr. Ma’s research is dedicated to three-level prevention and control of birth defects, fertility preservation in cancer patients, and the application of genetic screening in reproductive health. She explores the mechanisms behind endometriosis, recurrent pregnancy loss, and infertility, aiming to develop innovative treatment protocols. Her contributions to preimplantation genetic testing (PGT) and reproductive immunology have significantly influenced reproductive healthcare in China and beyond.

🏆 Awards and Recognitions

Dr. Ma has been recognized for her outstanding contributions to reproductive medicine and has received multiple accolades at the national and provincial levels. She is an esteemed member of leading reproductive medicine societies and has played a crucial role in shaping policies related to ART in China. She has also been actively involved in national academic conferences, furthering research and clinical advancements in reproductive health.

📚 Publications

Dr. Ma has published over 30 research articles in SCI-indexed and Chinese core journals. Below are some of her notable publications:

  1. Guan, D., Sun, W., Gao, M., Chen, Z., & Ma, X. (2024). Immunologic insights in recurrent spontaneous abortion: Molecular mechanisms and therapeutic interventions. Biomedicine & Pharmacotherapy, 177, p.117082. [Cited by articles]
  2. Liu, L., Liu, Y., Tian, Y., Cao, Y., Wang, T., Mi, S., Yang, R., Liu, S., Ma, X., & Wang, J. (2024). Identification of differentially expressed mRNAs and lncRNAs contributes to elucidation of underlying pathogenesis and therapeutic strategy of recurrent implantation failure. Reproductive Sciences, pp.1-14. [Cited by articles]
  3. Wang, T., Zhang, L., Gao, W., Liu, Y., Yue, F., Ma, X., & Liu, L. (2024). Transcriptome-wide N6-methyladenosine modification profiling of long non-coding RNAs in patients with recurrent implantation failure. BMC Medical Genomics, 17(1), p.251. [Cited by articles]
  4. Guan, D., Zhao, L., Shi, X., Ma, X., & Chen, Z. (2023). Copper in cancer: from pathogenesis to therapy. Biomedicine & Pharmacotherapy, 163, p.114791. [Cited by articles]

🔚 Conclusion

Dr. Xiaoling Ma is a pioneering figure in reproductive medicine, dedicated to advancing ART and genetic screening technologies. Her extensive clinical expertise, innovative research, and leadership in reproductive medicine make her a highly respected figure in her field. Through her work, she continues to impact countless lives, improving fertility treatments and reproductive healthcare policies. Her commitment to teaching, research, and patient care ensures a lasting legacy in reproductive medicine.

Anquan Shang | Medicine | Best Researcher Award

Posted on by sciencefather

Prof. Anquan Shang | Medicine | Best Researcher Award

The Second People’s Hospital of Lianyungang | China

Prof. Anquan Shang is a distinguished Associate Chief Laboratory Technician and Clinical Laboratory Physician with an H-index of 26. At the age of 39, he has made significant contributions to the field of clinical laboratory diagnostics. As a master’s supervisor, he plays a crucial role in mentoring future medical professionals. He is currently affiliated with Shanghai Jiao Tong University and has extensive experience in tumor marker research and clinical diagnostics.

Profile👤

ORCID

Google Scholar

Scopus

Strengths for the Awards✨

  • Strong Research Productivity 

    • H-index of 26, indicating high citation impact.
    • Over 70 SCI and core journal publications as first or corresponding author.
    • Multiple high-impact factor papers in oncology, microbiology, and immunology.

  • Impressive Funding & Grants 

    • Secured multiple national and provincial-level research grants.
    • Led and participated in 13+ major projects in oncology, infection, and precision diagnostics.

  • Leadership & Recognition 

    • Head of key clinical departments and training programs in prestigious hospitals.
    • Recognized in Shanghai and Jiangsu talent programs, highlighting academic excellence.

  • Significant Innovations & Impact 

    • Contributions to liquid biopsy, tumor biomarkers, and infection diagnostics.
    • 5+ patents, demonstrating translational research impact.

  • Professional Network & Influence 

    • Active in national and international research communities.
    • Reviewer and editor for multiple scientific journals.

🎓 Education

His academic journey began with a specialization in medical laboratory technology at Xiangfan Vocational and Technical College (2005-2008). He then pursued a bachelor’s degree in medical laboratory science at Jiangsu University (2011-2014), followed by a master’s degree in clinical laboratory diagnostics at Ningxia Medical University (2014-2017). He furthered his expertise with a Ph.D. in clinical laboratory diagnostics from Tongji University (2017-2020), establishing a strong foundation for his research career.

🏥 Experience

Currently, he is a postdoctoral researcher in clinical laboratory diagnostics at Ruijin Hospital, affiliated with Shanghai Jiao Tong University (2025-present), focusing on tumor biomarker research. Since 2023, he has led the Clinical Laboratory Medicine Department at Lianyungang Second People’s Hospital, a key clinical specialty in Jiangsu Province. Previously, he completed another postdoctoral fellowship at Tongji University (2020-2022), researching tumor microenvironment and biomarkers. His clinical experience spans roles as a laboratory technician at various hospitals between 2008 and 2014, steadily advancing to leadership positions.

🔬 Research Interests On Medicine

His research focuses on:

1️⃣ Tumor immunology 🧬

2️⃣ Infection microecology and immune microenvironment remodeling 🦠

3️⃣ Precision molecular diagnostics for chronic diseases 🏥

4️⃣ Liquid biopsy techniques for early disease detection 💉

🏆 Awards

He has received numerous prestigious awards, including the Yancheng City Natural Science Achievement Award (3 times), the Yancheng Medical New Technology Introduction Award (5 times), and the Huaihai Science and Technology Progress Award (2nd Prize, twice). From 2019-2022, he was consecutively recognized as an Outstanding Young Scientific Researcher by the Shanghai Medical Association Laboratory Medicine Branch.

📚 Publications

  • Title: Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p-TGF-β1 axis
    Authors: A Shang, C Gu, W Wang, X Wang, J Sun, B Zeng, C Chen, W Chang, …
    Publication Year: 2020
    Citations: 372

  • Title: Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils
    Authors: A Shang, W Wang, C Gu, C Chen, B Zeng, Y Yang, P Ji, J Sun, J Wu, …
    Publication Year: 2019
    Citations: 147

  • Title: Exosomal KRAS mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression
    Authors: A Shang, C Gu, C Zhou, Y Yang, C Chen, B Zeng, J Wu, W Lu, W Wang, …
    Publication Year: 2020
    Citations: 100

  • Title: Tumor microenvironment: lactic acid promotes tumor development
    Authors: Y Gao, H Zhou, G Liu, J Wu, Y Yuan, A Shang
    Publication Year: 2022
    Citations: 80

  • Title: Exosomal miR-183-5p promotes angiogenesis in colorectal cancer by regulation of FOXO1
    Authors: A Shang, X Wang, C Gu, W Liu, J Sun, B Zeng, C Chen, P Ji, J Wu, …
    Publication Year: 2020
    Citations: 77

  • Title: Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer
    Authors: AQ Shang, J Wu, F Bi, YJ Zhang, LR Xu, LL Li, FF Chen, WW Wang, …
    Publication Year: 2017
    Citations: 77

  • Title: Knockdown of long noncoding RNA PVT1 suppresses cell proliferation and invasion of colorectal cancer via upregulation of microRNA-214-3p
    Authors: AQ Shang, WW Wang, YB Yang, CZ Gu, P Ji, C Chen, BJ Zeng, JL Wu, …
    Publication Year: 2019
    Citations: 70

  • Title: IGF2BP2 promotes the progression of colorectal cancer through a YAP‐dependent mechanism
    Authors: J Cui, J Tian, W Wang, T He, X Li, C Gu, L Wang, J Wu, A Shang
    Publication Year: 2021
    Citations: 62

  • Title: miR‐381‐3p restrains cervical cancer progression by downregulating FGF7
    Authors: A Shang, C Zhou, G Bian, W Chen, W Lu, W Wang, D Li
    Publication Year: 2019
    Citations: 62

  • Title: Vaginal microecological characteristics of women in different physiological and pathological period
    Authors: L Shen, W Zhang, Y Yuan, W Zhu, A Shang
    Publication Year: 2022
    Citations: 59

🔚 Conclusion

With a strong academic background, leadership in clinical laboratory medicine, and groundbreaking research in tumor immunology and molecular diagnostics, he continues to make significant contributions to medical science. His extensive experience, prestigious awards, and influential publications highlight his dedication to advancing clinical diagnostics and improving patient outcomes.

Yang Xu | Medicine | Best Researcher Award

Posted on by sciencefather

Dr. Yang Xu | Medicine | Best Researcher Award

Associate chief physician | Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital | China

Yang Xu is an Associate Chief Physician, Associate Professor, and Graduate Supervisor at the Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital. Specializing in the early diagnosis and personalized treatment of lung tumors, Dr. Xu has made significant contributions to respiratory medicine and oncology. As a leading expert in the field, he has played a pivotal role in advancing immune purification and cell therapy, earning widespread recognition for his scientific achievements.

Profile

ORCID

Strengths for the Awards

✅ Expertise in Lung Tumor Diagnosis & Treatment: Yang Xu specializes in the early diagnosis and personalized treatment of lung tumors, which is a crucial area in respiratory and critical care medicine.

✅ Strong Research Contributions: With 6 funded research projects, including National Natural Science Foundation of China and key national R&D plans, his research impact is significant.

✅ Recognition & Patents: Winning 1 medical science and technology progress award and holding 4 national invention patents showcase his innovation and contribution to medical advancements.

✅ Publication Record: Publishing 40 research papers, including 20 SCI-indexed papers, and editing 5 monographs as a deputy principal author indicates a high level of scholarly contribution.

✅ Leadership & Influence: Holding leadership positions in prestigious medical associations such as the Chinese Medical Association and Beijing Medical Association reflects his influence in the field.

🎓 Education

Dr. Xu received his medical education and advanced training in respiratory and critical care medicine, equipping him with the expertise to diagnose and treat complex lung diseases. His academic journey has been marked by rigorous research and continuous professional development in cutting-edge medical technologies.

👨‍⚕️ Experience

With extensive experience in respiratory and critical care medicine, Dr. Xu has led multiple national research projects, including those funded by the National Natural Science Foundation of China and the national key R&D plan. As an esteemed educator and mentor, he has guided numerous students in the field, shaping the next generation of medical professionals. His leadership extends to prestigious roles such as Deputy Leader of the Immune Purification and Cell Therapy Group under the Chinese Medical Association and Deputy Chairman of the Lung Cancer Group in the Respiratory Branch of the Beijing Medical Association.

🔬 Research Interests On Medicine

Dr. Xu’s research focuses on:

  • Lung Tumor Diagnosis & Treatment – Advancing early detection and precision therapy.
  • Immune Checkpoint Inhibitor Pneumonia – Contributing to China’s first expert consensus.
  • Strategic Advanced Electronic Materials – Investigating innovative medical applications.
  • Immune Purification & Cell Therapy – Exploring novel therapeutic strategies in respiratory medicine.

🏆 Awards

Dr. Xu has received numerous accolades for his contributions to medical science, including:

  • Medical Science & Technology Progress Award 🏅
  • 4 National Invention Patents 🏅🏅🏅🏅
  • Excellent Doctor & Excellent Teacher Titles 🏆 (Multiple times)
  • Selected as China’s High-Level Scientific and Technological Innovation Talent 🌟

📚 Publications

  1. Clinic Examination and Gene Diagnosis for a Birt–Hogg–Dubé Syndrome Family With a Novel flcn Frameshift Mutation Causing Nonsense‐Mediated mRNA Degradation
    • Authors: Yang Xu, Jie Gao, Yang An, Chenxi Zou, Guoqing Ding, Guohua Yang
    • Year: 2025
  2. [Clinical diagnosis and treatment of lung cancer combined with interstitial lung disease]
    • Author: Xu Y
    • Year: 2024
  3. Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer
    • Authors: Yabin Chen, Fang Z, Tang Y, Jin Y, Guo C, Hu L, Xu Y, Ma X, Gao J, Xie M et al.
    • Year: 2021
  4. Clinical characteristics of patients with chronic eosinophilic pneumonia in a Chinese tertiary-care hospital: A 6-year retrospective study
    • Authors: Xu Y, Wang Z, Li W, Zhu Q, Liang Z
    • Year: 2021
  5. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis
    • Authors: Huang A, Xu Y, Zang X, Wu C, Gao J, Sun X, Xie M, Ma X, Deng H, Song J et al.
    • Year: 2021
  6. Perfluorocarbon Protects against Lipopolysaccharide-Induced Apoptosis of Endothelial Cells in Pulmonary Microvessels
    • Authors: Xu Y, Wu T, Wang P, Liang ZX, Shi SS, Xu SF, Liu XJ, Tian Q
    • Year: 2021
  7. Lung cancer treatment in the era of immunotherapy
    • Authors: Xu Y, Liang-an Chen
    • Year: 2020
  8. The efficacy and safety of low-frequency rotating static magnetic field therapy combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded, controlled clinical trial
    • Authors: Minghui Zhu, Yang Z, Hang Yu, Zhu Q, Xu Y, Li Y, Li C, Zhao W, Zhixin Liang, Liang-an Chen
    • Year: 2020
  9. Identification of differentially expressed genes in hip cartilage with femoral head necrosis, based on genome‑wide expression profiles
    • Authors: Li WC, Bai L, Xu Y, Xu RJ, Hou WB
    • Year: 2019
  10. Cystic and solitary nodular pulmonary metastases in a patient with low-grade endometrial stromal sarcoma: A case report and literature review
  • Authors: Xu Y, Zhixin Liang, Guo JT, Su X, Lu YL, Guan XZ
  • Year: 2019

🔚 Conclusion

Yang Xu is a distinguished leader in respiratory and critical care medicine, driving innovation in lung cancer treatment and immune-related diseases. His contributions to research, education, and clinical practice continue to shape the future of respiratory medicine, making a lasting impact on both national and global healthcare communities.